NAUT stock forecast, quote, news & analysis
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome... Show more
Nautilus Biotechnology (NAUT) Stock Analysis: Voyager Platform Gains Traction
Key Takeaways
- Nautilus Biotechnology unveiled its Voyager proteomics platform, targeting beta access in the second half of 2026 and full commercial launch thereafter.
- Baylor College of Medicine became the first early access customer, validating the platform's potential in multi-omics research.
- Q4 2025 earnings showed a reduced cash burn rate, with $156 million in cash providing runway through 2027.
- Guggenheim raised its price target to $4, maintaining a Buy rating amid platform progress.
- Stock has surged over 270% in the past year, reflecting investor enthusiasm for proteomics advancements.
Current Market Snapshot
Nautilus Biotechnology (NAUT) has experienced significant volatility in recent trading sessions, driven by milestones in its single-molecule proteomics platform. The stock has shown strength amid broader biotech sector interest in innovative tools for proteome analysis, with shares trading near the upper end of recent ranges. Investor sentiment remains positive following key announcements on platform commercialization and early customer adoption. While pre-revenue as a development-stage company, Nautilus maintains a solid cash position, supporting ongoing R&D and field evaluations. Market cap hovers around $440 million, positioning it as a speculative play in life sciences tools.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of 25 top-performing AI trading bots out of over 350 available on the platform, chosen by advanced AI algorithms to match current market conditions. These bots trade thousands of tickers across diverse strategies, timeframes from 5 minutes to daily, and styles including hedging, sector-specific plays, and leveraged ETFs. Performance highlights include annualized returns ranging from 15% to over 120%, win rates of 54% to 88%, and profit factors up to 12.21. Examples feature bots targeting semiconductors like SOXL and ASML, energy giants such as XOM and CVX, aerospace including RKLB and LMT, and small-cap signals. With real-time signals, risk management, and copy-trading options, these bots offer investors data-driven tools to navigate volatility. Explore the page to identify bots aligning with your strategy and market outlook.
Recent Developments Driving NAUT Price Action
Nautilus Biotechnology (NAUT), a development-stage life sciences firm pioneering single-molecule proteomics, has seen robust price appreciation in recent weeks, fueled by pivotal updates on its Voyager platform. The stock, which has climbed over 270% in the past year and nearly 80% year-to-date, reflects growing confidence in the company's path to commercialization.
On February 24, 2026, Nautilus unveiled the Voyager platform at the US Human Proteome Organization (HUPO) conference, showcasing its core instrument for single-molecule iterative mapping after successful field testing at the Buck Institute for Research on Aging. This revelation, enabling high-resolution protein isoform quantification, targets beta access in the second half of 2026 and full launch thereafter, sparking initial enthusiasm and contributing to upward momentum.
Two days later, on February 26, the company reported Q4 and full-year 2025 financial results, posting an EPS of -$0.11, better than the prior year's -$0.14. Cash burn improved to $50.2 million for the year from $57.8 million, with $156.1 million in cash equivalents and investments extending runway through 2027. Management guided for 15-20% operating expense growth in 2026 to support commercialization, bolstering investor views on financial discipline amid no revenue generation.
Analyst response was swift: Guggenheim raised its price target from $2.50 to $4 on February 27, reiterating Buy, citing platform validation. This helped sustain gains despite biotech sector pressures.
Progress accelerated in March. On March 2, Nautilus appointed Amber Faust, a proteomics sales veteran from Olink and SomaLogic, as VP of Sales to drive Voyager adoption, signaling commercial readiness and adding to positive sentiment.
The standout catalyst came March 18: Baylor College of Medicine joined as the first Early Access Program customer, selecting Voyager for an NIH-funded multi-omics toolkit focused on protein isoforms in cancer research. This real-world validation drove sharp intraday surges, underscoring demand from academic leaders.
Nautilus capped the period with a March 24 announcement of participation in the Investor Summit Group Virtual Conference, providing further visibility. No major macroeconomic or regulatory headwinds directly impacted NAUT, though broader biotech funding trends supported speculative interest. These developments collectively shifted sentiment from R&D focus to near-term revenue potential, propelling shares despite high volatility.
2026 Outlook and Key Factors to Monitor
As Nautilus Biotechnology advances through 2026, investors should track milestones tied to the Voyager platform's beta rollout in the second half, including early access program expansion beyond Baylor College of Medicine. Successful field deployments and additional customer wins could validate single-molecule proteomics' utility in areas like neurodegeneration and oncology, building on collaborations with the Michael J. Fox Foundation and Allen Institute.
Financially, the $156 million cash reserve supports projected 15-20% expense growth for platform scaling and sales buildup, with runway into 2027. Monitor quarterly burn rates and any capital raises amid pre-revenue status. Analyst consensus points to a $4 price target, reflecting optimism on commercialization.
Risks include technical delays in proteoform assays, competitive pressures from established proteomics players, and biotech sector funding dynamics. Opportunities lie in partnerships for broader proteome mapping and regulatory progress toward clinical applications. Strategic hiring like VP Sales Amber Faust positions Nautilus for market entry, while industry shifts toward multi-omics integration favor its technology.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
NAUT's Stochastic Oscillator is remaining in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NAUT advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAUT as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NAUT turned negative on June 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
NAUT moved below its 50-day moving average on May 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAUT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NAUT entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.971) is normal, around the industry mean (18.441). P/E Ratio (0.000) is within average values for comparable stocks, (36.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.683). NAUT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (357.610).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NAUT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAUT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology